MTRI InMed Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—
Margins
Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—
Returns
ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x
Leverage & solvency
Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $820,188 | $1.12M | $1.30M | $1.26M | $1.11M |
| Cost of revenue | — | — | — | $635,994 | $716,962 | $728,056 | $1.09M | $650,813 |
| Gross profit | — | — | — | $184,194 | $403,159 | $576,654 | $175,625 | $460,894 |
| R&D expense | $206,015 | $805,741 | $1.02M | $630,636 | $575,458 | $577,254 | $425,370 | $895,176 |
| SG&A expense | $1.80M | $2.36M | $1.74M | $1.62M | $1.24M | $1.26M | $1.58M | $1.72M |
| Pretax income | -$2.00M | -$4.84M | -$2.79M | -$2.03M | -$1.83M | -$1.83M | -$2.07M | -$2.58M |
| Net income | -$2.33M | -$5.84M | -$2.97M | -$2.03M | -$1.73M | -$1.79M | -$2.12M | -$2.58M |
| EPS (basic) | -0.42 | — | -0.73 | -0.51 | -0.44 | — | -1.94 | -3.64 |
| EPS (diluted) | -0.42 | — | -0.73 | -0.51 | -0.44 | — | -1.94 | -3.64 |
| Weighted avg. shares (diluted) | 5.47M | — | 4.05M | 3.95M | 3.95M | — | 1.10M | 706,546 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.09M | $2.19M | $5.16M | $6.95M | $8.68M | $10.74M | $4.68M | $3.42M |
| Short-term investments | $40,331 | $39,670 | $41,625 | $42,675 | $42,859 | $43,384 | $40,582 | $40,787 |
| Receivables | — | — | — | $182,967 | $343,469 | $465,104 | $367,813 | $262,569 |
| Inventory | — | — | — | $947,898 | $890,807 | $961,173 | $813,970 | $1.10M |
| Current assets | $1.26M | $2.68M | $6.89M | $8.79M | $10.80M | $12.87M | $6.41M | $5.47M |
| PP&E, net | — | $221,037 | $642,884 | $764,254 | $881,549 | $992,199 | $1.11M | $1.23M |
| Intangibles | — | — | $1.50M | $1.54M | $1.58M | $1.62M | $1.66M | $1.70M |
| Total assets | $1.31M | $3.03M | $9.13M | $11.19M | $13.36M | $15.58M | $9.28M | $8.50M |
| Current liabilities | — | $1.96M | $2.21M | $1.48M | $1.55M | $1.84M | $1.84M | $1.79M |
| Total liabilities | $2.51M | $1.96M | $2.24M | $1.60M | $1.77M | $2.15M | $2.26M | $2.32M |
| Shareholders' equity | -$1.20M | $1.08M | $6.89M | $9.59M | $11.59M | $13.43M | $7.02M | $6.18M |
| Shares outstanding | 5.49M | 5.34M | 3.31M | 2.80M | 2.60M | 2.00M | 1.21M | 724,152 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.14M | -$2.96M | -$1.70M | -$2.38M | -$1.93M | -$1.78M | -$1.66M | -$2.50M |
| Investing cash flow | $2,417 | — | — | — | — | — | — | — |
| Financing cash flow | $40,000 | -$1 | $231,675 | $0 | -$137,178 | $8.17M | $2.92M | $338,521 |
| Depreciation & amortization | $168 | $48,359 | $51,707 | $53,201 | $53,202 | $52,752 | $51,706 | $53,202 |
| Stock-based compensation | $16,375 | $22,626 | $38,771 | $25,564 | $20,205 | $26,730 | $40,454 | $23,159 |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.